443 related articles for article (PubMed ID: 15037111)
1. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
[TBL] [Abstract][Full Text] [Related]
2. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
Wang RF; Gagliuso DJ; Mittag TW; Podos SM
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
[TBL] [Abstract][Full Text] [Related]
3. New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents.
Nakajima T; Matsugi T; Goto W; Kageyama M; Mori N; Matsumura Y; Hara H
Biol Pharm Bull; 2003 Dec; 26(12):1691-5. PubMed ID: 14646172
[TBL] [Abstract][Full Text] [Related]
4. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
[TBL] [Abstract][Full Text] [Related]
5. Effect of flunarizine, a calcium channel blocker, on intraocular pressure and aqueous humor dynamics in monkeys.
Wang RF; Gagliuso DJ; Podos SM
J Glaucoma; 2008; 17(1):73-8. PubMed ID: 18303390
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
Sharif NA; McLaughlin MA; Kelly CR; Katoli P; Drace C; Husain S; Crosson C; Toris C; Zhan GL; Camras C
Exp Eye Res; 2009 Mar; 88(3):386-97. PubMed ID: 18992242
[TBL] [Abstract][Full Text] [Related]
7. Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans.
Ishii K; Tomidokoro A; Nagahara M; Tamaki Y; Kanno M; Fukaya Y; Araie M
Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2957-63. PubMed ID: 11687542
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
Ota T; Murata H; Sugimoto E; Aihara M; Araie M
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2006-11. PubMed ID: 15914616
[TBL] [Abstract][Full Text] [Related]
9. Effects of prostanoid EP agonists on mouse intraocular pressure.
Saeki T; Ota T; Aihara M; Araie M
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2201-8. PubMed ID: 19117925
[TBL] [Abstract][Full Text] [Related]
10. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
Fuwa M; Ueda K; Akaishi T; Yamashita N; Kirihara T; Shimazaki A; Mano H; Kawazu K
PLoS One; 2016; 11(7):e0158797. PubMed ID: 27383260
[TBL] [Abstract][Full Text] [Related]
11. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey.
Nilsson SF; Drecoll E; Lütjen-Drecoll E; Toris CB; Krauss AH; Kharlamb A; Nieves A; Guerra T; Woodward DF
Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):4042-9. PubMed ID: 16936121
[TBL] [Abstract][Full Text] [Related]
12. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
[TBL] [Abstract][Full Text] [Related]
13. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice.
Ota T; Aihara M; Saeki T; Narumiya S; Araie M
Br J Ophthalmol; 2007 May; 91(5):673-6. PubMed ID: 17124244
[TBL] [Abstract][Full Text] [Related]
14. Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys.
Kurashima H; Asai Y; Aihara M; Ishida N; Nakamura M; Araie M
J Glaucoma; 2012 Feb; 21(2):123-8. PubMed ID: 21423041
[TBL] [Abstract][Full Text] [Related]
15. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
[TBL] [Abstract][Full Text] [Related]
16. Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow.
Woodward DF; Nilsson SF; Toris CB; Kharlamb AB; Nieves AL; Krauss AH
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3320-8. PubMed ID: 19234340
[TBL] [Abstract][Full Text] [Related]
17. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice.
Ota T; Aihara M; Narumiya S; Araie M
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4159-63. PubMed ID: 16249494
[TBL] [Abstract][Full Text] [Related]
18. Effects of topical phenylephrine and tafluprost on optic nerve head circulation in monkeys with unilateral experimental glaucoma.
Mayama C; Ishii K; Saeki T; Ota T; Tomidokoro A; Araie M
Invest Ophthalmol Vis Sci; 2010 Aug; 51(8):4117-24. PubMed ID: 20357196
[TBL] [Abstract][Full Text] [Related]
19. Ocular hypotensive and aqueous outflow-enhancing effects of AL-3037A (sodium ferri ethylenediaminetetraacetate).
Pang IH; Moll H; McLaughlin MA; Knepper PA; De Santis L; Epstein DL; Clark AF
Exp Eye Res; 2001 Dec; 73(6):815-25. PubMed ID: 11846512
[TBL] [Abstract][Full Text] [Related]
20. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
